{
    "info": {
        "nct_id": "NCT04176198",
        "official_title": "A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis",
        "inclusion_criteria": "Patients must meet all of the following inclusion criteria to be eligible:\n\nNuvisertib (TP-3654) Monotherapy Arm:\n\n* Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF\n* Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor\n* Fulfill the following clinical laboratory parameters:\n* Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions\n* ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors\n* Peripheral blood blast count < 5%\n* ECOG performance status ≤ 1\n* Life expectancy ≥ 6 months\n* Adequate renal function\n* Adequate hepatic function\n* Adequate coagulation function\n* Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.\n* Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF\n* Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF\n\nNuvisertib (TP-3654) + Ruxolitinib Arm:\n\n* Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF\n* On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response\n* Fulfills the following clinical laboratory parameters:\n* Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)\n* ANC ≥ 1 × 109/L without assistance of granulocyte growth factors\n* Peripheral blood blast count < 5% at screening\n* Adequate renal function\n* Adequate hepatic function\n* Adequate coagulation function\n* Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1\n* At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0\n* ECOG performance status ≤ 1\n* Life expectancy ≥ 6 months\n\nNuvisertib (TP-3654) + Momelotinib Arm\n\n* Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF\n* Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma\n* Fulfills the following clinical laboratory parameters:\n* Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline\n* Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)\n* ANC ≥ 1 × 109/L without assistance of granulocyte growth factors\n* Peripheral blood blast count < 5% at screening\n* Adequate renal function\n* Adequate hepatic function\n* Adequate coagulation function\n* Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1\n* At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0\n* ECOG performance status ≤ 1\n* Life expectancy ≥ 6 months\n\nPatients meeting any one of these exclusion criteria will be prohibited from participating in this study:\n\nNuvisertib (TP-3654) Monotherapy Arm:\n\n* Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).\n* Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.\n* Splenic irradiation within 6 months prior to Screening or prior splenectomy.\n* Prior allogeneic stem cell transplant within the last 6 months.\n* Eligible for allogeneic bone marrow or stem cell transplantation.\n* Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment\n* History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.\n* Corrected QT interval > 480msec.\n* Prior or concurrent malignancy that could interfere with the investigational regime.\n* Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.\n* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)\n* Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.\n* Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.\n* Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).\n* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.\n* Pregnant or breastfeeding\n* Currently receiving any other investigational agent.\n\nNuvisertib (TP-3654) + Ruxolitinib Arm:\n\n* Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).\n* Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)\n* Known allergic reactions or sensitivity to nuvisertib, or similar compound.\n* Splenic irradiation within 6 months prior to Screening or prior splenectomy\n* Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).\n* Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)\n* Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1\n* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)\n* Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).\n* Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)\n* History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1\n* Corrected QTcF of > 480 msec\n* Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention\n* History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea\n* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding\n* Pregnant or breastfeeding\n\nNuvisertib (TP-3654) + Momelotinib Arm:\n\n* Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).\n* Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).\n* Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention\n* Splenic irradiation within 6 months prior to screening or prior splenectomy\n* Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).\n* Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).\n* Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1\n* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)\n* Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)\n* Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)\n* Presence of Grade ≥ 2 peripheral neuropathy\n* History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1\n* Corrected QTcF of > 480 msec\n* Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention\n* History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea\n* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding\n* Pregnant or breastfeeding\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Fulfills the following clinical laboratory parameters:",
            "criterions": [
                {
                    "exact_snippets": "Fulfills the following clinical laboratory parameters",
                    "criterion": "clinical laboratory parameters",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 25 x 10^9 /L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "x 10^9 /L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without assistance of growth factors or platelet transfusions",
                    "criterion": "platelet count support",
                    "requirements": [
                        {
                            "requirement_type": "support",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate coagulation function",
            "criterions": [
                {
                    "exact_snippets": "Adequate coagulation function",
                    "criterion": "coagulation function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF",
            "criterions": [
                {
                    "exact_snippets": "Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF",
                    "criterion": "myelofibrosis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "primary myelofibrosis (PMF)",
                                "post-polycythemia vera myelofibrosis (post-PV-MF)",
                                "post-essential thrombocythemia myelofibrosis (post-ET-MF)"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "intermediate or high-risk primary or secondary MF",
                    "criterion": "myelofibrosis risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": [
                                "intermediate",
                                "high"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤ 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤ 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Nuvisertib (TP-3654) + Ruxolitinib Arm:",
            "criterions": [
                {
                    "exact_snippets": "Nuvisertib (TP-3654) + Ruxolitinib Arm",
                    "criterion": "treatment arm assignment",
                    "requirements": [
                        {
                            "requirement_type": "assigned treatment",
                            "expected_value": [
                                "Nuvisertib (TP-3654)",
                                "Ruxolitinib"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate coagulation function",
            "criterions": [
                {
                    "exact_snippets": "Adequate coagulation function",
                    "criterion": "coagulation function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QTcF of > 480 msec",
            "criterions": [
                {
                    "exact_snippets": "Corrected QTcF of > 480 msec",
                    "criterion": "corrected QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤ 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤ 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤ 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤ 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥ 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergic reactions or sensitivity to nuvisertib, or similar compound.",
            "criterions": [
                {
                    "exact_snippets": "Known allergic reactions or sensitivity to nuvisertib",
                    "criterion": "allergic reactions or sensitivity to nuvisertib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergic reactions or sensitivity to ... similar compound",
                    "criterion": "allergic reactions or sensitivity to similar compound",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)",
            "criterions": [
                {
                    "exact_snippets": "Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc)",
                    "criterion": "chronic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "portal hypertension or any of its complications",
                    "criterion": "portal hypertension or its complications",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Child-Pugh C",
                    "criterion": "Child-Pugh score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": "C"
                        }
                    ]
                },
                {
                    "exact_snippets": "auto-immune hepatitis",
                    "criterion": "auto-immune hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alpha-1 anti-trypsin deficiency",
                    "criterion": "alpha-1 anti-trypsin deficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Wilson's disease",
                    "criterion": "Wilson's disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Abnormal liver morphology at baseline imaging may require additional testing",
                    "criterion": "abnormal liver morphology at baseline imaging",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peripheral blood blast count < 5% at screening",
            "criterions": [
                {
                    "exact_snippets": "Peripheral blood blast count < 5% at screening",
                    "criterion": "peripheral blood blast count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1",
                    "criterion": "systemic antimicrobial therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": "required"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 1 week prior to Cycle 1 Day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Nuvisertib (TP-3654) Monotherapy Arm:",
            "criterions": [
                {
                    "exact_snippets": "Nuvisertib (TP-3654) Monotherapy Arm",
                    "criterion": "treatment arm assignment",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": "Nuvisertib (TP-3654) monotherapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF",
            "criterions": [
                {
                    "exact_snippets": "At least 2 symptoms measurable with each score of ≥ 3",
                    "criterion": "MFSAF symptom scores",
                    "requirements": [
                        {
                            "requirement_type": "number of symptoms with score ≥ 3",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "symptoms"
                            }
                        },
                        {
                            "requirement_type": "score per symptom",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "a total average score of ≥ 10 per MFSAF",
                    "criterion": "MFSAF total average score",
                    "requirements": [
                        {
                            "requirement_type": "total average score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction ... within 6 months prior to Cycle 1 Day 1",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": "within 6 months prior to Cycle 1 Day 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure ... within 6 months prior to Cycle 1 Day 1",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": "within 6 months prior to Cycle 1 Day 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": "within 6 months prior to Cycle 1 Day 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": "echocardiogram"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 4 weeks prior to Cycle 1 Day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.",
            "criterions": [
                {
                    "exact_snippets": "History of symptomatic congestive heart failure",
                    "criterion": "symptomatic congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1",
                    "criterion": "uncontrolled arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "echocardiogram"
                        },
                        {
                            "requirement_type": "time since assessment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.",
                    "criterion": "spleen volume",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 450,
                                "unit": "cm3"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "MRI",
                                "CT scan"
                            ]
                        },
                        {
                            "requirement_type": "assessment_timeframe",
                            "expected_value": "within 2 weeks prior to Cycle 1 Day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Splenic irradiation within 6 months prior to screening or prior splenectomy",
            "criterions": [
                {
                    "exact_snippets": "Splenic irradiation within 6 months prior to screening",
                    "criterion": "splenic irradiation",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "timing reference",
                            "expected_value": "prior to screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior splenectomy",
                    "criterion": "splenectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).",
            "criterions": [
                {
                    "exact_snippets": "Received previous systemic antineoplastic therapy (other than ruxolitinib) ... within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1",
                    "criterion": "previous systemic antineoplastic therapy (other than ruxolitinib)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Received ... any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1",
                    "criterion": "previous experimental therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with nuvisertib is not allowed",
                    "criterion": "prior treatment with nuvisertib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1",
                    "criterion": "prior treatment with hydroxyurea or anagrelide",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥ 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.",
            "criterions": [
                {
                    "exact_snippets": "Exhibited allergic reactions or sensitivity to nuvisertib",
                    "criterion": "allergic reactions or sensitivity to nuvisertib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergic reactions or sensitivity to ... similar compound",
                    "criterion": "allergic reactions or sensitivity to similar compound",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).",
            "criterions": [
                {
                    "exact_snippets": "Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1",
                    "criterion": "previous systemic antineoplastic therapy or any experimental therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1",
                    "criterion": "hydroxyurea or anagrelide use",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥ 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).",
            "criterions": [
                {
                    "exact_snippets": "Eligible for allogeneic bone marrow or stem cell transplantation",
                    "criterion": "allogeneic bone marrow or stem cell transplantation eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are not willing to undergo transplantation ... are considered as transplant ineligible",
                    "criterion": "willingness to undergo transplantation",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for whom a suitable donor is not available are considered as transplant ineligible",
                    "criterion": "availability of suitable donor for transplantation",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peripheral blood blast count < 5%",
            "criterions": [
                {
                    "exact_snippets": "Peripheral blood blast count < 5%",
                    "criterion": "peripheral blood blast count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Nuvisertib (TP-3654) Monotherapy Arm:",
            "criterions": [
                {
                    "exact_snippets": "Nuvisertib (TP-3654) Monotherapy Arm",
                    "criterion": "treatment arm assignment",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": "Nuvisertib (TP-3654) monotherapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)",
            "criterions": [
                {
                    "exact_snippets": "Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 1 week prior to Cycle 1 Day 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Topical, inhaled, nasal, and ophthalmic steroids are not prohibited",
                    "criterion": "topical, inhaled, nasal, and ophthalmic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Splenic irradiation within 6 months prior to Screening or prior splenectomy",
            "criterions": [
                {
                    "exact_snippets": "Splenic irradiation within 6 months prior to Screening",
                    "criterion": "splenic irradiation",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "timing reference",
                            "expected_value": "prior to Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior splenectomy",
                    "criterion": "splenectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently receiving any other investigational agent.",
            "criterions": [
                {
                    "exact_snippets": "Currently receiving any other investigational agent",
                    "criterion": "receipt of other investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).",
            "criterions": [
                {
                    "exact_snippets": "Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 1 week prior to the first dose of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "topical, inhaled, nasal, and ophthalmic steroids are not prohibited",
                    "criterion": "topical, inhaled, nasal, and ophthalmic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior or concurrent malignancy that could interfere with the investigational regime.",
            "criterions": [
                {
                    "exact_snippets": "Prior or concurrent malignancy that could interfere with the investigational regime",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "temporal occurrence",
                            "expected_value": [
                                "prior",
                                "concurrent"
                            ]
                        },
                        {
                            "requirement_type": "potential to interfere with investigational regime",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.",
            "criterions": [
                {
                    "exact_snippets": "Known history of chronic liver disease",
                    "criterion": "chronic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "portal hypertension",
                    "criterion": "portal hypertension",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Child-Pugh C",
                    "criterion": "Child-Pugh score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": "C"
                        }
                    ]
                },
                {
                    "exact_snippets": "auto-immune hepatitis",
                    "criterion": "auto-immune hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alpha-1 anti-trypsin deficiency",
                    "criterion": "alpha-1 anti-trypsin deficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Wilson's disease",
                    "criterion": "Wilson's disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "viral",
                                "fungal"
                            ]
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1",
                    "criterion": "infection treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": "parenteral antimicrobial"
                        },
                        {
                            "requirement_type": "treatment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before Cycle 1 Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.",
            "criterions": [
                {
                    "exact_snippets": "Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies",
                    "criterion": "anemia due to iron, vitamin B12, or folate deficiencies",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune or hereditary hemolytic anemia",
                    "criterion": "autoimmune hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune or hereditary hemolytic anemia",
                    "criterion": "hereditary hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "thalassemia",
                    "criterion": "thalassemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe GI bleeding",
                    "criterion": "severe GI bleeding",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention",
            "criterions": [
                {
                    "exact_snippets": "Known allergic reactions or sensitivity to nuvisertib",
                    "criterion": "allergic reactions or sensitivity to nuvisertib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known allergic reactions or sensitivity to ... momelotinib",
                    "criterion": "allergic reactions or sensitivity to momelotinib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known allergic reactions or sensitivity to ... any structurally similar drug",
                    "criterion": "allergic reactions or sensitivity to any structurally similar drug",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known allergic reactions or sensitivity to ... any component of the formulations of either study intervention",
                    "criterion": "allergic reactions or sensitivity to any component of the formulations of either study intervention",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QTcF of > 480 msec",
            "criterions": [
                {
                    "exact_snippets": "Corrected QTcF of > 480 msec",
                    "criterion": "corrected QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding",
            "criterions": [
                {
                    "exact_snippets": "Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies",
                    "criterion": "anemia due to iron, vitamin B12, or folate deficiencies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune or hereditary hemolytic anemia",
                    "criterion": "autoimmune hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune or hereditary hemolytic anemia",
                    "criterion": "hereditary hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "thalassemia",
                    "criterion": "thalassemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe GI bleeding",
                    "criterion": "severe GI bleeding",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention",
            "criterions": [
                {
                    "exact_snippets": "Prior or concurrent malignancy",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior",
                                "concurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "could interfere with the safety or efficacy assessment of the study intervention",
                    "criterion": "potential interference with safety or efficacy assessment of the study intervention",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF",
            "criterions": [
                {
                    "exact_snippets": "Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF",
                    "criterion": "myelofibrosis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "PMF",
                                "post-PV-MF",
                                "post-ET-MF"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "intermediate or high-risk primary or secondary MF",
                    "criterion": "myelofibrosis risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": [
                                "intermediate",
                                "high"
                            ]
                        },
                        {
                            "requirement_type": "MF type",
                            "expected_value": [
                                "primary",
                                "secondary"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).",
            "criterions": [
                {
                    "exact_snippets": "Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1",
                    "criterion": "previous systemic antineoplastic therapy or any experimental therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with momelotinib or nuvisertib is not allowed",
                    "criterion": "prior treatment with momelotinib or nuvisertib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week",
                    "criterion": "ongoing JAK inhibitor therapy at screening",
                    "requirements": [
                        {
                            "requirement_type": "taper period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper",
                    "criterion": "patients on a low dose of ruxolitinib (eg, 5 mg QD)",
                    "requirements": [
                        {
                            "requirement_type": "taper period",
                            "expected_value": "reduced or no taper"
                        }
                    ]
                },
                {
                    "exact_snippets": "hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1",
                    "criterion": "hydroxyurea or anagrelide use",
                    "requirements": [
                        {
                            "requirement_type": "last dose before Cycle 1 Day 1",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding",
            "criterions": [
                {
                    "exact_snippets": "Known clinically significant anemia due to iron ... deficiencies",
                    "criterion": "anemia due to iron deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known clinically significant anemia due to ... vitamin B12 ... deficiencies",
                    "criterion": "anemia due to vitamin B12 deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known clinically significant anemia due to ... folate deficiencies",
                    "criterion": "anemia due to folate deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known clinically significant ... autoimmune ... hemolytic anemia",
                    "criterion": "autoimmune hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known clinically significant ... hereditary hemolytic anemia",
                    "criterion": "hereditary hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known clinically significant ... thalassemia",
                    "criterion": "thalassemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known clinically significant ... severe GI bleeding",
                    "criterion": "severe GI bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of Grade ≥ 2 peripheral neuropathy",
            "criterions": [
                {
                    "exact_snippets": "Presence of Grade ≥ 2 peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)",
            "criterions": [
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "viral hepatitis A infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "viral hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "viral hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "testing for hepatitis B and C are required",
                    "criterion": "hepatitis B infection testing",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "testing for hepatitis B and C are required",
                    "criterion": "hepatitis C infection testing",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell transplant within the last 6 months",
                    "criterion": "prior allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have relapsed after 6 months post-transplant and do not have active GVHD",
                    "criterion": "relapse after allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "relapse status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "do not have active GVHD",
                    "criterion": "active GVHD",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1",
            "criterions": [
                {
                    "exact_snippets": "Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1",
                    "criterion": "splenomegaly (spleen volume)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 450,
                                "unit": "cm3"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "MRI",
                                "CT scan"
                            ]
                        },
                        {
                            "requirement_type": "assessment_timeframe",
                            "expected_value": "within 2 weeks prior to Cycle 1 Day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell transplant within the last 6 months.",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell transplant within the last 6 months.",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1",
                    "criterion": "parenteral antimicrobial therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before Cycle 1 Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1",
            "criterions": [
                {
                    "exact_snippets": "Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1",
                    "criterion": "splenomegaly",
                    "requirements": [
                        {
                            "requirement_type": "spleen volume",
                            "expected_value": {
                                "operator": ">=",
                                "value": 450,
                                "unit": "cm3"
                            }
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "MRI",
                                "CT scan"
                            ]
                        },
                        {
                            "requirement_type": "assessment timing",
                            "expected_value": "within 2 weeks prior to Cycle 1 Day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)",
            "criterions": [
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "hepatitis A infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "testing for hepatitis B and C are required",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "testing for hepatitis B and C are required",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).",
            "criterions": [
                {
                    "exact_snippets": "Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc)",
                    "criterion": "chronic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "portal hypertension",
                    "criterion": "portal hypertension",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Child-Pugh C",
                    "criterion": "Child-Pugh C liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "auto-immune hepatitis",
                    "criterion": "auto-immune hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alpha-1 anti-trypsin deficiency",
                    "criterion": "alpha-1 anti-trypsin deficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Wilson's disease",
                    "criterion": "Wilson's disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Abnormal liver morphology at baseline imaging",
                    "criterion": "abnormal liver morphology at baseline imaging",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligible for allogeneic bone marrow or stem cell transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Eligible for allogeneic bone marrow or stem cell transplantation.",
                    "criterion": "eligibility for allogeneic bone marrow or stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea",
            "criterions": [
                {
                    "exact_snippets": "History of a medical condition ... that could impair absorption",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential to impair absorption",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... GI tract surgery that could impair absorption",
                    "criterion": "GI tract surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential to impair absorption",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... GI tract surgery that ... could result in short bowel syndrome with diarrhea",
                    "criterion": "GI tract surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential to result in short bowel syndrome with diarrhea",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention",
            "criterions": [
                {
                    "exact_snippets": "Prior or concurrent malignancy",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior",
                                "concurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "could interfere with the safety or efficacy assessment of the study intervention",
                    "criterion": "potential interference with safety or efficacy assessment of the study intervention",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QT interval > 480msec.",
            "criterions": [
                {
                    "exact_snippets": "Corrected QT interval > 480msec.",
                    "criterion": "corrected QT interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF",
            "criterions": [
                {
                    "exact_snippets": "At least 2 symptoms measurable (score ≥ 1) using the MF-SAF",
                    "criterion": "number of symptoms measurable by MF-SAF",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "symptoms"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "score ≥ 1) using the MF-SAF",
                    "criterion": "symptom score by MF-SAF",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline",
            "criterions": [
                {
                    "exact_snippets": "Anemic, defined as Hb <10 g/dL",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring RBC transfusion at baseline",
                    "criterion": "RBC transfusion requirement at baseline",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate coagulation function",
            "criterions": [
                {
                    "exact_snippets": "Adequate coagulation function",
                    "criterion": "coagulation function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0",
            "criterions": [
                {
                    "exact_snippets": "At least 2 symptoms measurable with each score ≥ 3",
                    "criterion": "MFSAF v4.0 symptom scores",
                    "requirements": [
                        {
                            "requirement_type": "number of symptoms with score ≥ 3",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "symptoms"
                            }
                        },
                        {
                            "requirement_type": "individual symptom score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "score"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "a total average score of ≥ 10 per MFSAF v4.0",
                    "criterion": "MFSAF v4.0 total average score",
                    "requirements": [
                        {
                            "requirement_type": "total average score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "score"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)",
            "criterions": [
                {
                    "exact_snippets": "Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment",
                    "criterion": "non-hematological adverse events related to prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stable Grade 2 conditions may be permitted in consultation with the Sponsor",
                    "criterion": "stable Grade 2 non-hematological adverse events related to prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "permission by Sponsor",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)",
            "criterions": [
                {
                    "exact_snippets": "Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment",
                    "criterion": "non-hematological adverse events related to prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        },
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stable Grade 2 conditions may be permitted in consultation with the Sponsor",
                    "criterion": "stable Grade 2 non-hematological adverse events related to prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "permission by Sponsor",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)",
            "criterions": [
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "viral hepatitis A infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "viral hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic active or acute viral hepatitis A, B, or C infection",
                    "criterion": "viral hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "testing for hepatitis B and C are required",
                    "criterion": "hepatitis B infection testing",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "testing for hepatitis B and C are required",
                    "criterion": "hepatitis C infection testing",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peripheral blood blast count < 5% at screening",
            "criterions": [
                {
                    "exact_snippets": "Peripheral blood blast count < 5% at screening",
                    "criterion": "peripheral blood blast count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥ 1 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without assistance of granulocyte growth factors",
                    "criterion": "granulocyte growth factor assistance",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Nuvisertib (TP-3654) + Momelotinib Arm",
            "criterions": [
                {
                    "exact_snippets": "Nuvisertib (TP-3654) + Momelotinib Arm",
                    "criterion": "treatment arm assignment",
                    "requirements": [
                        {
                            "requirement_type": "assigned treatment",
                            "expected_value": [
                                "Nuvisertib (TP-3654)",
                                "Momelotinib"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)",
            "criterions": [
                {
                    "exact_snippets": "Eligible for allogeneic bone marrow or stem cell transplantation",
                    "criterion": "allogeneic bone marrow or stem cell transplantation eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are not willing to undergo transplantation",
                    "criterion": "willingness to undergo transplantation",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for whom a suitable donor is not available",
                    "criterion": "availability of suitable donor",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.",
            "criterions": [
                {
                    "exact_snippets": "Medical condition ... that could impair absorption",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "impairment of absorption",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "GI tract surgery that could impair absorption",
                    "criterion": "GI tract surgery",
                    "requirements": [
                        {
                            "requirement_type": "impairment of absorption",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "short bowel syndrome with diarrhea",
                    "criterion": "short bowel syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diarrhea",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fulfill the following clinical laboratory parameters:",
            "criterions": [
                {
                    "exact_snippets": "Fulfill the following clinical laboratory parameters",
                    "criterion": "clinical laboratory parameters",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Previously treated with JAK inhibitor(s)",
                    "criterion": "JAK inhibitor treatment history",
                    "requirements": [
                        {
                            "requirement_type": "previous treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is intolerant ... to the JAK inhibitor(s)",
                    "criterion": "JAK inhibitor intolerance",
                    "requirements": [
                        {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "resistant ... to the JAK inhibitor(s)",
                    "criterion": "JAK inhibitor resistance",
                    "requirements": [
                        {
                            "requirement_type": "resistance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory ... to the JAK inhibitor(s)",
                    "criterion": "JAK inhibitor refractoriness",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has lost response to the JAK inhibitor(s)",
                    "criterion": "JAK inhibitor response loss",
                    "requirements": [
                        {
                            "requirement_type": "loss of response",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is ineligible to be treated with JAK inhibitor",
                    "criterion": "JAK inhibitor treatment eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Splenic irradiation within 6 months prior to Screening or prior splenectomy.",
            "criterions": [
                {
                    "exact_snippets": "Splenic irradiation within 6 months prior to Screening",
                    "criterion": "splenic irradiation",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior splenectomy",
                    "criterion": "splenectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Nuvisertib (TP-3654) + Momelotinib Arm:",
            "criterions": [
                {
                    "exact_snippets": "Nuvisertib (TP-3654) + Momelotinib Arm",
                    "criterion": "treatment arm assignment",
                    "requirements": [
                        {
                            "requirement_type": "assigned treatment",
                            "expected_value": [
                                "Nuvisertib (TP-3654)",
                                "Momelotinib"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Nuvisertib (TP-3654) + Ruxolitinib Arm:",
            "criterions": [
                {
                    "exact_snippets": "Nuvisertib (TP-3654) + Ruxolitinib Arm",
                    "criterion": "treatment arm assignment",
                    "requirements": [
                        {
                            "requirement_type": "assigned treatment",
                            "expected_value": [
                                "Nuvisertib (TP-3654)",
                                "Ruxolitinib"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment",
            "criterions": [
                {
                    "exact_snippets": "Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment",
                    "criterion": "non-hematological toxicity related to prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0",
            "criterions": [
                {
                    "exact_snippets": "At least 2 symptoms measurable with each score of ≥ 3 ... per MFSAF v4.0",
                    "criterion": "MFSAF v4.0 symptom scores",
                    "requirements": [
                        {
                            "requirement_type": "number of symptoms with score ≥ 3",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "symptoms"
                            }
                        },
                        {
                            "requirement_type": "score per symptom",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "score"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "a total average score of ≥ 10 per MFSAF v4.0",
                    "criterion": "MFSAF v4.0 total average score",
                    "requirements": [
                        {
                            "requirement_type": "average score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "score"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks prior to Cycle 1 Day 1",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have not recovered adequately from surgery prior to first dose",
                    "criterion": "recovery from surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks prior to Cycle 1 Day 1",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have not recovered adequately prior to first dose",
                    "criterion": "recovery from major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea",
            "criterions": [
                {
                    "exact_snippets": "History of a medical condition ... that could impair absorption",
                    "criterion": "medical condition impairing absorption",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... GI tract surgery that could impair absorption",
                    "criterion": "GI tract surgery impairing absorption",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... GI tract surgery that ... could result in short bowel syndrome with diarrhea",
                    "criterion": "GI tract surgery resulting in short bowel syndrome with diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fulfills the following clinical laboratory parameters:",
            "criterions": [
                {
                    "exact_snippets": "Fulfills the following clinical laboratory parameters",
                    "criterion": "clinical laboratory parameters",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF",
            "criterions": [
                {
                    "exact_snippets": "Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF",
                    "criterion": "myelofibrosis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "PMF",
                                "post-PV-MF",
                                "post ET-MF"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "intermediate or high-risk primary or secondary MF",
                    "criterion": "myelofibrosis risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": [
                                "intermediate",
                                "high"
                            ]
                        },
                        {
                            "requirement_type": "MF type",
                            "expected_value": [
                                "primary",
                                "secondary"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks prior to Cycle 1 Day 1",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not recovered adequately from from surgery prior to first dose",
                    "criterion": "recovery from surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response",
            "criterions": [
                {
                    "exact_snippets": "On ruxolitinib treatment for ≥ 6 months",
                    "criterion": "ruxolitinib treatment duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib",
                    "criterion": "stable ruxolitinib dose",
                    "requirements": [
                        {
                            "requirement_type": "dose_range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "mg BID"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 25,
                                        "unit": "mg BID"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has either lost response or had a suboptimal or plateau in response",
                    "criterion": "response to ruxolitinib",
                    "requirements": [
                        {
                            "requirement_type": "response_status",
                            "expected_value": [
                                "lost response",
                                "suboptimal response",
                                "plateau in response"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma",
            "criterions": [
                {
                    "exact_snippets": "Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks",
                    "criterion": "prior JAK inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "JAK inhibitor type",
                            "expected_value": "approved JAK inhibitor (except momelotinib)"
                        },
                        {
                            "requirement_type": "disease indication",
                            "expected_value": [
                                "PMF",
                                "Post-PV MF",
                                "Post-ET MF"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks",
                    "criterion": "prior JAK inhibitor treatment with transfusion requirement",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "transfusion requirement",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "units of red blood cells in 8 weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 4 weeks if JAK inhibitor therapy was complicated by ... Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma",
                    "criterion": "prior JAK inhibitor treatment with Grade 3/4 adverse events",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "adverse event severity",
                            "expected_value": [
                                "Grade 3",
                                "Grade 4"
                            ]
                        },
                        {
                            "requirement_type": "adverse event type",
                            "expected_value": [
                                "thrombocytopenia",
                                "anemia",
                                "hematoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).",
            "criterions": [
                {
                    "exact_snippets": "Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 1 week prior to Cycle 1 Day 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Topical, inhaled, nasal, and ophthalmic steroids are not prohibited",
                    "criterion": "topical, inhaled, nasal, and ophthalmic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 50 × 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without assistance of growth factors or platelet transfusions",
                    "criterion": "platelet count support",
                    "requirements": [
                        {
                            "requirement_type": "support",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction ... within 6 months prior to Cycle 1 Day 1",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure ... within 6 months prior to Cycle 1 Day 1",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).",
            "criterions": [
                {
                    "exact_snippets": "Prior allogenic stem cell transplant within the last 6 months",
                    "criterion": "prior allogenic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed after 6 months post-transplant and do not have active GVHD",
                    "criterion": "relapse status and active GVHD status post-transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "relapse status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "active GVHD status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 50 × 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "× 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without assistance of growth factors or platelet transfusions",
                    "criterion": "platelet count support",
                    "requirements": [
                        {
                            "requirement_type": "support",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:",
            "criterions": []
        },
        {
            "line": "* ANC ≥ 1 × 109/L without assistance of granulocyte growth factors",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥ 1 × 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "× 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without assistance of granulocyte growth factors",
                    "criterion": "granulocyte growth factor assistance",
                    "requirements": [
                        {
                            "requirement_type": "assistance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ANC ≥ 1 × 109/L without assistance of granulocyte growth factors",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥ 1 × 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "× 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without assistance of granulocyte growth factors",
                    "criterion": "granulocyte growth factor assistance",
                    "requirements": [
                        {
                            "requirement_type": "assistance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Patients must meet all of the following inclusion criteria to be eligible:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}